Alza Corporation

Other

Alza Coporation

George V Guittard

Patrick S Wong

Felix T Theeuwes

David J Kidney

Fernando E Gumucio

Francisco Jao

Susan M Marks

Atul D Ayer

Richard Lewis Cortese

Jerry D Childers

Paul R Magruder

Anthony L Kuczynski

Jeremy C Wright

Felix A Landrau

Joseph C Deters

Glen E Barclay

Patrick S-l Wong

Harold M Leeper

Patrick S L Wong

Lawrence G Hamel

Howard A Carpenter

Ernest S Quan

L G Hamel

Larry G Hamel

A composition and a dosage form are disclosed comprising oxybutynin alone/or accompanied by another drug indicated for therapy. A method is disclosed for administering oxybutynin alone/or accompanied by a different drug or for administering oxybutynin and a different drug according to a therapeutic program for the management of incontinence alone, and for other therapy.

Method for the management of incontinence

An osmotic caplet is disclosed comprising an osmotic caplet exit for delivering a preselected dose of drug to a patient in need of therapy.

Osmotic caplet

A hydrocodone composition, a hydrocodone dosage form, and a method of administering hydrocodone are disclosed and indicated for hydrocodone therapy.

Hydrocodone therapy

A composition comprising oxybutynin, a dosage form comprising oxybutynin, and a method for administering oxybutynin are disclosed for oxybutynin therapy.

Oxybutynin therapy

A dosage form is disclosed for administering 10 ng to 1200 mg tacrine to a patient in need of tacrine therapy.

Therapy for neurological diseases

A composition comprising oxybutynin, a device comprising oxybutynin, and a method for administering oxybutynin are disclosed for oxybutynin therapy.

Dosage form and method for treating incontinence

Method of therapy comprising an osmotic caplet

Dosage form comprising oxybutynin

Tacrine therapy

A composition comprising oxybutynin and a device comprising oxybutynin are disclosed for oxybutynin therapy.

A drug delivery device is disclosed for delivering a drug to the intestine and the colon. The device comprises external means for delaying the delivery of drug in the stomach, and hydrophobic means for preventing the passage of fluid through the delay means.

Dosage form for delivering drug at a controlled rate to the intestine

A dosage form is disclosed for delivering pentoxifylline to a patient in need of pentoxifylline therapy. A method is discussed for delivery pentoxifylline to a patient at a dosage form controlled rate over an extended period of time.

Pentoxifylline therapy and method of use

Pentoxifylline therapy

Growing community of inventors

Cupertino, CA, United States of America

George V Guittard